Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKinsey
Dow
Colorcon
Express Scripts

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Marizomib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Marizomib?

Marizomib is an investigational drug.

There have been 9 clinical trials for Marizomib. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2018.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Glioblastoma, and Multiple Myeloma. The leading clinical trial sponsors are Triphase Research and Development I Corporation, National Cancer Institute (NCI), and European Organisation for Research and Treatment of Cancer - EORTC.

There are two hundred and ninety-four US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Marizomib
TitleSponsorPhase
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord EpendymomaNational Cancer Institute (NCI)Phase 2
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed GlioblastomaCelgenePhase 3
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed GlioblastomaEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 3

See all Marizomib clinical trials

Clinical Trial Summary for Marizomib

Top disease conditions for Marizomib
Top clinical trial sponsors for Marizomib

See all Marizomib clinical trials

US Patents for Marizomib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Marizomib   Start Trial Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells Selecta Biosciences, Inc. (Watertown, MA)   Start Trial
Marizomib   Start Trial Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
Marizomib   Start Trial Methods and compositions for inhibition of Ras ARAXES PHARMA LLC (San Diego, CA)   Start Trial
Marizomib   Start Trial Salt formulations for the fermentation of marine microorganisms Celgene International II Sarl (Couvet, CH)   Start Trial
Marizomib   Start Trial Anti-tigit antibodies and methods of use Genentech, Inc. (South San Francisco, CA)   Start Trial
Marizomib   Start Trial Pyrrolidine amide compounds as histone demethylase inhibitors GENENTECH, INC. (South San Francisco, CA) CONSTELLATION PHARMACEUTICALS INC. (Cambridge, MA)   Start Trial
Marizomib   Start Trial TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Marizomib

Drugname Country Document Number Estimated Expiration Related US Patent
Marizomib Australia 2011279250 2030-07-12   Start Trial
Marizomib Australia 2012249401 2030-07-12   Start Trial
Marizomib Australia 2012249419 2030-07-12   Start Trial
Marizomib Australia 2012249493 2030-07-12   Start Trial
Marizomib Australia 2012249537 2030-07-12   Start Trial
Marizomib Australia 2012249540 2030-07-12   Start Trial
Marizomib Australia 2012249544 2030-07-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Mallinckrodt
Medtronic
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.